Subjects with documented STEMI research hub

A Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in subjects with ST-elevation myocardial infarction in the pre-hospital setting

This study is testing a new drug, zalunfiban, for people having a severe heart attack (STEMI). It aims to see if a single injection given early helps improve recovery and is safe. The drug is compared to a placebo (dummy drug).